This protocol addresses otitis externa in patients with a known or suspected perforation of the tympanic membrane, or who have a tympanostomy tube in place — and in whom first-line topical management has not resulted in adequate symptom relief.
When the tympanic membrane is not intact, only non-ototoxic preparations are appropriate for topical use. Initial management in this population includes a non-ototoxic topical preparation — specifically quinolone otic drops, the only topical antimicrobials approved for middle ear use — together with analgesic therapy and aural toilet or wick placement when the ear canal is obstructed.
Prior therapy: Non-ototoxic topical quinolone otic drops, analgesic treatment, and aural toilet or wick placement as needed.
Goal not reached: Symptom improvement — including otalgia, itching, and fullness — within 48 to 72 hours of initiating topical management.
When these targets are not met, escalation beyond topical-only management is indicated.
The escalated approach involves systemic therapy — an oral antibiotic chosen specifically for coverage of the key gram-negative and gram-positive organisms associated with refractory otitis externa in this setting. The complete selection criteria, specific agent, and full treatment algorithm are available in the structured protocol.
When the patient has a known or suspected perforation of the tympanic membrane, including a tympanostomy tube, the clinician should prescribe a non-ototoxic topical preparation.
Any obstruction should be addressed with aural toilet, wick placement, or both, or, if the obstruction cannot be relieved, systemic therapy is begun with an oral antibiotic that covers P aeruginosa and S aureus.
View source ↗